Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a balanced view, with posts praising the initial safety profile and promising response rates, as evidenced by phrases like 'recently published' and mentions of 'preliminary efficacy.' The tone indicates a respectful acknowledgment of the study's significance, while questions about further research imply a cautious optimism rather than overstatement of impact.
Most discussions recognize the positive preliminary results of YSCH-01, indicating general agreement on the promising safety and efficacy data.
The interest level is moderate, with posters showing curiosity about the trial, its authors, and the potential significance of the findings.
The engagement is moderate, as several posts mention specific details about the study, authors, and related articles, showing some depth of discussion.
The perceived impact is relatively modest, as the discussions focus on early-stage results and the importance of further research rather than immediate clinical application.
New #JITC article: Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial https://t.co/StsmsGkpQ9 https://t.co/mFxfGnmCvh
Meet the Author: Xueping Cao from Shanghai Yuansong Biotechnology Co is co-author of “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tumors: An Investigator-Initiated Trial,” recently published in #JITC! 1/6 https://t.co/qcQnswBJG5
Here’s a closer look at recent #JITC article “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tumors: An Investigator-Initiated Trial” by @DrHKRaza from @Amgen @DaiichiSankyoUS @cgoncology @Oncolytics @virogin. 1/10 https://t.co/82z7DnWHC4
Meet the Author: Yanqiu Liu (@handle) from Shanghai Yuansong Biotechnology Co. is co-author of “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tumors: An Investigator-Initiated Trial,” recently published in #JITC! 1/6 https://t.co/r1ifojM6Nz
Meet the Author: Dr. Hafiz Khuram Raza (@DrHKRaza) from Shanghai Yuansong Biotechnology Co is co-author of “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tumors: An Investigator-Initiated Trial,” recently published in #JITC! 1/5 https://t.co/yh6AlelqyC
RT @jitcancer: New #JITC article: Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initia…
This study evaluates the safety and initial effectiveness of YSCH01, a recombinant LIFN adenovirus, in patients with advanced solid tumors. Results indicate it is safe and shows promising activity, warranting further…
Meet the Author: Xueping Cao from Shanghai Yuansong Biotechnology Co is co-author of “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tumors: An Investigator-Initiated Trial,” recently published in #JITC! 1/6 https://t.co/qcQnswBJG5
Meet the Author: Dr. Hafiz Khuram Raza (@DrHKRaza) from Shanghai Yuansong Biotechnology Co is co-author of “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tumors: An Investigator-Initiated Trial,” recently published in #JITC! 1/5 https://t.co/yh6AlelqyC
Meet the Author: Yanqiu Liu (@handle) from Shanghai Yuansong Biotechnology Co. is co-author of “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tumors: An Investigator-Initiated Trial,” recently published in #JITC! 1/6 https://t.co/r1ifojM6Nz
RT @jitcancer: Here’s a closer look at recent #JITC article “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tum…
RT @jitcancer: Here’s a closer look at recent #JITC article “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tum…
Here’s a closer look at recent #JITC article “Preliminary Efficacy and Safety of YSCH-01 in Patients with Advanced Solid Tumors: An Investigator-Initiated Trial” by @DrHKRaza from @Amgen @DaiichiSankyoUS @cgoncology @Oncolytics @virogin. 1/10 https://t.co/82z7DnWHC4
Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial https://t.co/U610ltzsp0
RT @jitcancer: New #JITC article: Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initia…
RT @jitcancer: New #JITC article: Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initia…
RT @jitcancer: New #JITC article: Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initia…
RT @jitcancer: New #JITC article: Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initia…
New #JITC article: Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial https://t.co/StsmsGkpQ9 https://t.co/mFxfGnmCvh